Overview

Study of Tadalafil Once-a-Day for 12 Weeks in Japanese Men With Benign Prostatic Hyperplasia Followed by an Open-Label Extension

Status:
Completed

Trial end date:
2010-04-01

Target enrollment:

Participant gender:

Summary

This study is a randomized, double-blind, placebo-controlled, parallel-design to compare the efficacy and safety of tadalafil once-a-day dosing versus placebo for 12 weeks followed by an open-label extension to evaluate the long-term safety and efficacy of tadalafil in Japanese men with signs and symptoms of benign prostatic hyperplasia.

Phase:

Phase 2

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Tadalafil